Judge Cold To Otsuka's Exclusivity Claims In FDA Row
A D.C. federal judge on Thursday was harshly skeptical of Otsuka's bid to reverse the U.S. Food and Drug Administration's approval of a rival version of its schizophrenia drug Abilify Maintena,...To view the full article, register now.
Already a subscriber? Click here to view full article